View Older Stories View More Recent Stories

Jul 27, 2017 07:00AM TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan
Jul 25, 2017 04:15PM TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017
Jun 29, 2017 09:00AM TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference
Jun 28, 2017 09:00AM TESARO Announces Lonnie Moulder and Mary Lynne Hedley Named EY Entrepreneurs of the Year® New England
Jun 26, 2017 04:15PM TESARO Joins Healthcare Businesswomen’s Association as Corporate Partner
Jun 7, 2017 04:30PM TESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference
Jun 3, 2017 06:30PM TESARO Provides Business and Pipeline Update at ASCO Investor Briefing
May 25, 2017 04:16PM TESARO (TSRO) Announces Presentations of Abstracts at ASCO
May 25, 2017 04:15PM Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2017 09:01AM National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community
May 11, 2017 02:01AM TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer
May 1, 2017 08:31AM TESARO (TSRO) Submits IND Application for TSR-033 to FDA
May 1, 2017 08:30AM TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
Apr 27, 2017 08:25AM TESARO (TSRO) Says Clinical Trial of TSR-042 has been Expanded to Enroll Patients with MSI-H Endometrial Cancer
Apr 27, 2017 08:15AM TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
Apr 26, 2017 08:34AM TESARO's (TSRO) VARUBY Approved by European Commission
Apr 26, 2017 08:30AM TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
Apr 25, 2017 04:15PM Tesaro Announces Participation in Two Investor Conferences
Apr 25, 2017 04:15PM TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017
Apr 19, 2017 04:21PM TESARO (TSRO) Says Zejula is Now Available in U.S.
Apr 19, 2017 04:15PM TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.
Apr 7, 2017 08:30AM Tesaro Wins Awards for Clinical Development Team of the Year and Clinical Partnership of the Year
Mar 27, 2017 03:50PM TESARO (TSRO) Announces FDA Approval of its PARP Inhibitor, ZEJULA, for Treatment of Women With Recurrent Ovarian Cancer
Mar 27, 2017 03:47PM TESARO Announces U.S. FDA Approval Of ZEJULA™ (Niraparib) For Women With Recurrent Ovarian Cancer
Mar 27, 2017 03:46PM TESARO (TSRO) to Expand Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cance
Mar 27, 2017 03:45PM TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cancer
Mar 27, 2017 03:39PM FDA gave TESARO (TSRO) Zejula a Broad Label for Ovarian Cancer Maintenance, BRCA Mutation & Non -Adam Feuerstein
Feb 27, 2017 06:17AM TESARO (TSRO) Announces Positive CHMP Opinion for VARUBY
Feb 27, 2017 02:00AM TESARO Receives Positive CHMP Opinion for VARUBY®
Feb 21, 2017 04:15PM TESARO Announces Participation at Two Investor Conferences
Jan 17, 2017 08:03AM TESARO (TSRO) Niraparib EAP Opens in U.S. for Ovarian Cancer
Jan 17, 2017 08:01AM Tesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer
Dec 20, 2016 08:01AM TESARO (TSRO) Announces Priority FDA Review for for Niraparib NDA
Dec 20, 2016 08:00AM Tesaro Announces Priority Review Designation for Niraparib NDA
Nov 21, 2016 04:05PM Tesaro Announces Participation in Three Investor Conferences
Nov 3, 2016 04:05PM TESARO Announces Third-Quarter 2016 Operating Results
Nov 1, 2016 04:30PM Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian Cancer
Oct 24, 2016 04:05PM TESARO Announces Participation in Three Investor Conferences
Oct 10, 2016 12:57PM Unusual 11 Mid-Day Movers 10/10: (EGAS) (MCUR) (TSRO) Higher; (TWTR) (TWLO) (MYGN) Lower
Oct 10, 2016 09:17AM Pre-Open Stock Movers 10/10: (IPCI) (TSRO) (MYL) Higher; (TWTR) (BMY) (DOV) Lower (more...)
Oct 10, 2016 06:58AM TESARO (TSRO), ENGOT Announce Niraparib Phase 3 ENGOT-OV16/NOVA Met Primary Endpoint
Oct 10, 2016 06:40AM TESARO (TSRO) Presents Statistically Significant Phase 3 ENGOT-OV16/NOVA Trial Results at ESMO
Oct 8, 2016 02:15AM TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016
Sep 29, 2016 07:02AM TESARO (TSRO) Announces Collaboration with China's Zai Lab
Sep 29, 2016 07:01AM TESARO and Zai Lab Announce Collaboration, Development and License Agreement
Sep 12, 2016 08:03AM TESARO (TSRO) Announces Receipt of FDA Fast-Track Designation for Niraparib
Sep 12, 2016 08:01AM TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission
Sep 6, 2016 08:01AM TESARO Announces Six Data Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting
Aug 4, 2016 04:05PM Tesaro Announces Second-Quarter 2016 Operating Results
Jul 8, 2016 04:07PM TESARO (TSRO), ENGOT Announces Positive Data From ENGOT-OV16/NOVA Phase 3 Trial
View More Recent Stories View Older Stories